MUTANT DNA ENCODING INSULIN RECEPTOR SUBSTRATE 1

Abstract: DNA construct comprising a DNA sequence encoding insulin receptor substrate 1 (IRS-1), the DNA sequence containing a mutation of at least one nucleotide, or comprising a fragment of the DNA sequence including said mutation.

Description: MUTANT DNA ENCODING INSULIN RECEPTOR SUBSTRATE 1 FIELD OF INVENTION The present invention relates to a mutant DNA sequence encoding insulin receptor substrate 1, a method of detecting a mutation in the gene encoding insulin receptor substrate 1, as well as a diagnostic composition and a test kit for use in the method. BACKGROUND OF THE INVENTION Non-insulin-dependent diabetes mellitus (NIDDM) is a common endocrine disorder and a considerable body of evidence strongly suggests that genetic factors contribute to the pathogenesis (1) . Studies of patients with overt NIDDM and of individuals at high risk of NIDDM reveal abnormalities of both insulin secretion and insulin action (2) . However, a genetic defect at one or more loci in the cellular action of insulin and insulin- like growth factor 1 (IGF1) might well involve both the biochemical pathways of tissues that regulate insulin secretion and insulin sensitive hepatic and extrahepatic tissues that produce or extract glucose. Although more than twenty different mutations of the insulin receptor gene have been reported in syndromes of severe insulin resistance frequently associated with the skin disorder acanthosis nigricans or ovarian hyperandrogenism (17) , mutations in the insulin receptor molecule do not explain the genetic etiology of the common form of NIDDM. The common form of late onset NIDDM is a heterogeneous disorder where at least two major defects contribute to the pathophysiology of the phenotype: insulin resistance and insulin deficiency (2) . Most likely NIDDM is also polygenic and it is suggested that subsets of patients will display changes in various genes, in aggregate accounting for the inherited components of the disorder. The high cumulative risk of diabetes in offspring of NIDDM parents (30-50%) and the high concordance rate in identical twins (70-100%) underscore the significance of the genetic etiology of the disease (1) . Insulin initiates its cellular effects by binding to the a subunit of its tetrameric plasma membrane receptor (3) . The kinase in the β subunit is thereby activated which in turn catalyzes the intramolecular autophosphorylation of specific tyrosine residues of the β subunit, further stimulating the tyrosine kinase activity of the receptor towards other protein substrates in the cascade of insulin action. Recently, the first endogeneous substrate for the insulin receptor kinase (termed insulin receptor substrate 1, abbreviated to IRS-1) was cloned and sequenced (4-6) . The complementary DNA sequence encodes a cytoplasmic, hydrophilic protein of a relative molecular mass between 165 and 185 kD (27,28) which contains multiple phosphorylation sites. Besides being a substrate for the insulin receptor kinase, IRS-1 is also phosphorylated following the activation of the IGF1 receptor kinase (16) . IRS-1 is barely detectable in cells expressing few insulin receptors, but is strongly detected in cells expressing high levels of receptors and weakly detected in cells expressing mutant receptors defective in biological signalling (27,28). IRS-1 is a unique molecule containing 20 tyrosine phosphorylation consensus sequences, 6 of which appear in YMXM (Tyr-Met-X-Met) motifs. Following insulin stimulated tyrosine phosphorylation of YMXM motifs in the IRS-1 molecule, the phosphorylated IRS-l binds phosphatidylinositol 3-kinase (PI3- kinase) suggesting that IRS-1 acts as a multisite "docking" protein to bind signal proteins thereby linking the receptor kinase to insulin sensitive transporters and enzymes (7-15) . The PI3-kinase is composed of at least two subunits including a 110 kDa catalytic subunit and a 85 kDa regulatory protein which contains src homology 2 domains that mediate protein- protein interactions by binding to phosphotyrosine residues in various proteins (7-15) . Interestingly, it has been demons¬ trated that insulin causes the interaction between IRS-1 and PI-3 kinase via phosphorylated YMXM motifs of IRS-1 and src homology 2 domains of the 85 kDa regulatory subunit of PI-3 kinase. Moreover, overexpression of IRS-1 potentiates the activation of PI3-kinase in insulin stimulated cells, and tyrosyl phosphorylated IRS-1 or synthetic peptides containing phosphorylated YMXM motifs activate PI3-kinase in vitro. Besides being a substrate of the insulin receptor kinase, IRS-1 is also phosphorylated following the activation of the IGFl receptor kinase (16) . Hence, it has been suggested that IRS-1 by binding and regulating enzymes containing src homology 2 domains may play a critical role to select and differentiate the effects of insulin and IGFl from those of other tyrosine kinases and to generate diversity and amplification of signal transmission into multiple intracellular pathways (7-16) . SUMMARY OF THE INVENTION According to the present invention, it has surprisingly been found that a number of NIDDM patients carry mutations in the gene coding for IRS-1. It is at present assumed that one or more of the mutations may be involved in or associated with the etiology of NIDDM, and their presence may therefore be diagnostic for NIDDM and possibly also other disorders resulting from insulin resistance. Accordingly, the present invention relates to a DNA construct comprising a DNA sequence encoding insulin receptor substrate 1 (IRS-1) , the DNA sequence containing a mutation of at least one nucleotide, or comprising a fragment of the DNA sequence including said mutation. It is at present assumed that mutation of the IRS-1 gene may be indicative of abnormalities significant for the development of NIDDM or other disorders. For instance, the mutation may give rise to the substitution of an a ino acid in IRS-1 which may cause changes in the tertiary structure of IRS-1. Such changes may interfere with the normal interaction between the insulin or IGF-1 receptor kinase and one or more intracellular proteins regulating cellular metabolism and growth. These proteins typically have src homology 2 domains and include phosphatidyl inositol 3 kinase, GRB-2 and SHPTP-2 (vide M.F. White et al., Exp. Clin. Endocrinol. 101,, Suppl. 2, 1993, pp. 98-99, in particular Fig. 1) . Mutations may also interfere with the transcription or translation of the gene, or with the stability of the IRS-1 transcript. Alternatively, the mutation may be associated with (i.e. genetically linked with) the mutation which causes the disease. In another aspect, the present invention relates to a living system containing a DNA construct of the invention and capable of expressing IRS-1 wherein at least one amino acid is substituted. The living system, which may comprise a cell or a multicellular organism containing the appropriate signal transduction pathway, may be used to screen for substances which have an effect on insulin or IGF-1 stimulated signal transduction in the system. In a further aspect, the present invention relates to a method of detecting the presence of a mutation in the gene encoding IRS-1, the method comprising obtaining a biological sample from a subject and analysing the sample for a mutation of at least one nucleotide. Based on current knowledge, it is assumed that the present method may be used to diagnose predisposition to NIDDM in a subject as well as other disorders resulting from insulin resistance (such as android obesity, essential hypertension, dyslipidemia or atherosclerosis) . Biological samples may, for instance, be obtained from blood, serum, plasma or tissue,. The invention further relates to a diagnostic composition and a test kit for use in the method. DETAILED DESCRIPTION OF THE INVENTION In particular, the present invention relates to a DNA construct comprising a DNA sequence encoding IRS-1 and containing a mutation giving rise to at least one amino acid substitution in the IRS-1 protein sequence. The mutation may for instance be located at a site where the amino acid substitution interferes with signal transduction through IRS-1, as such a mutation is most likely to be involved in disease etiology. An example of such a DNA sequence is one containing a mutation of G to A in the first position of codon 972 of the IRS-1 gene. This mutation leads to substitution of glycine by arginine in position 972. The molecular mechanism by which the IRS-1 gene variant may lead to development of NIDDM is not known at present. However, compared with glycine, arginine is a much larger molecule and has a polar side chain with a positive charge and a high pKa of 12.5. In IRS-1, codon 972 is located between two YMXM motifs. Although the changes which the glycine for arginine substitution may cause in the tertiary structure of IRS-1 are not known at present, it is assumed that the steric and electrostatic changes of the IRS-1 mutant interfere with the normal interaction between insulin and IGF-1 mediated phosphorylation of neighbouring YMXM motifs of IRS-1 and signal transmitting proteins with src homology 2 domains. Alternatively, the mutation may be a marker associated with another mutation in this or another gene, which other mutation is the one actually involved in disease etiology. This may also be the case with the silent mutations found in the third position of codon 805 (A to G) and in the third position of codon 894 (G to C) . Clinical investigations have shown that NIDDM patients as a whole have insulin resistant glucose disposal to peripheral tissues when compared with glucose-tolerant control subjects. However, glycine 972 -mutation carriers with NIDDM did not differ in their degree of insulin resistance when compared with mutation-negative diabetic patients. Furthermore, the sensitivity of peripheral tissues to insulin was measured in 2 of 3 mutation-positive nondiabetics who turned out to have values of insulin sensitivity within the normal range. In contrast, all mutation carriers had remarkably low fasting plasma concentrations of insulin and C-peptide when compared with matched noncarriers. The combination of comparable insulin sensitivity of peripheral tissues and low basal levels of circulating 3-cell secretory products may indicate pancreatic /3-cell dysfunction. In a preferred embodiment, the DNA construct of the invention comprises the DNA sequence shown in the Sequence Listing as SEQ ID NO:l, or a fragment of said DNA sequence including the mutation of G to A at nucleotide 3494 of SEQ ID NO:l. The length of the DNA construct may vary widely depending on the intended use. For use as an oligonucleotide probe for hybridisation purposes, the DNA fragment may be as short as 17 nucleotides. For expression in a living system as defined above, the DNA construct will typically comprise the full- length DNA sequence encoding IRS-1. The DNA construct of the invention comprising the mutation in the DNA sequence encoding IRS-1 may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the IRS-1 by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed. , Cold Spring Harbor, 1989) . The probes used should be specific for the mutation. Alternatively, the DNA sequence encoding wild-type IRS-1 may be modified by site-directed mutagenesis using synthetic oligonucleotides containing the mutation for homologous recombination in accordance with well- known procedures. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202, or Saiki et al. , Science 239, 1988, pp. 487-491. The DNA construct of the invention may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 . (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 2 (1984), 801 - 805. According to the phosphoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed and ligated. This procedure may preferably be used to prepare fragments of the IRS-1 encoding DNA sequence. The recombinant expression vector into which the DNA construct is inserted may be any vector which may conveniently be subjected to recombinant DNA procedures. The choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated (e.g. a viral vector) . In the vector, the mutant DNA sequence encoding IRS-1 should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of. the mutant DNA encoding IRS-1 in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981) , 854 -864) , the MT-1 (metallothionein gene) promoter (Palmiter et al.. Science 222 (1983), 809 - 814) or the adeno- virus 2 major late promoter. The mutant DNA sequence encoding IRS-1 may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) . The vector may further comprise elements such as polyadenylation signals (e.g. from SV40 or the adenovirus 5 Elb region) , transcriptional enhancer sequences (e.g. the SV40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs) . The recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An example of such a sequence is the SV40 origin of replication. The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hygromycin or methotrexate. The procedures used to ligate the DNA sequences coding for IRS- 1, the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.) . In a further aspect, the present invention relates to a variant of IRS-1 containing at least one amino acid substitution, in particular a variant containing at least one amino acid substitution at a site where the substitution interferes with signal transduction through IRS-1, or a fragment thereof including said substitution. An example of such a variant is one in which glycine 972 is substituted by arginine, or a fragment thereof containing said substitution, e.g. the variant which has the amino acid sequence shown in the Sequence Listing as SEQ ID NO:2, or a fragment thereof containing Arg 972 . The living system into which the DNA construct of the invention is introduced may be a cell which is capable of producing IRS-1 and which has the appropriate signal transduction pathways. The cell is preferably a eukaryotic cell, such as a vertebrate cell, e.g. a Xenopus laevis oocyte or mammalian cell, in particular a mammalian cell. Examples of suitable mammalian cell lines are the COS (ATCC CRL 1650), BHK (ATCC CRL 1632, ATCC CCL 10), CHL (ATCC CCL39) or CHO (ATCC CCL 61) cell lines. Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159 (1982), 601 - 621; Southern and Berg, J. Mol. Appl. Genet, l (1982), 327 - 341; Loyter et al., Proc. Natl. Acad. Sci. USA 79 (1982), 422 - 426; Wigler et al., Cell .14 . (1978), 725; Corsaro and Pearson, Somatic Cell Genetics 7 (1981), 603, Graham and van der Eb, Virology 52 (1973), 456; and Neumann et al., EMBO J. 1 (1982), 841 - 845. The mutant DNA sequence encoding IRS-1 may then be expressed by culturing a cell as described above in a suitable nutrient medium under conditions which are conducive to the expression of the IRS-1-coding DNA sequence. The medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection) . The living system according to the invention may also comprise a transgenic animal. A transgenic animal is one in whose genome a heterologous DNA sequence has been introduced. In particular, the transgenic animal is a transgenic non-human mammal, mammals being generally provided with appropriate signal transduction pathways. The mammal may conveniently be a rodent such as a rat or mouse. The mutant DNA sequence encoding IRS-1 may be introduced into the transgenic animal by any one of the methods previously described for this purpose. Briefly, the DNA sequence to be introduced may be injected into a fertilised ovum or cell of an embryo which is subsequently implanted into a female mammal by standard methods, resulting in a transgenic mammal whose germ cells and/or somatic cells contain the mutant 5 DNA sequence. For a more detailed description of a method of producing transgenic mammals, vide B. Hogan et al., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. The mutant DNA sequence may also be introduced into the animal by transfection of fertilised ova 10 with a retrovirus containing the DNA sequence, cf. R. Jaenisch, Proc. Natl. Acad. Sci. USA 73, 1976, pp. 1260-1264. A further method of preparing transgenic animals is described in Gordon and Ruddle, Methods Enzymol. 101, 1983, pp. 411-432. In one embodiment of the present method of detecting the 15 presence of a mutation in the IRS-1 gene, a biological sample is obtained from a subject, DNA (in particular genomic DNA) is isolated from the sample and digested with a restriction endonuclease which cleaves DNA at the site of the mutation, and cleavage of the DNA within the gene encoding IRS-1 at this site 20 is determined. After digestion, the resulting DNA fragments may be subjected to electrophoresis on an agarose gel. DNA from the gel may then be blotted onto a nitrocellulose filter and hybridised with a radiolabelled probe. The probe may conveniently contain a DNA fragment of the IRS-1 gene spanning 25 the mutation (substantially according to the method of E.M. Southern, J. Mol. Biol. 98, 1975, pp. 503, e.g. as described by B.J. Conner et al., Proc. Natl. Acad. Sci. USA 80. 1983, pp. 278-282) . In a variant of this embodiment, the DNA isolated from the 30 sample may be amplified prior to digestion with the restriction endonuclease. Amplification may suitably be performed by poly erase chain reaction (PCR) using oligonucleotide primers based on the appropriate sequence of IRS-1 spanning the site(ε) of mutation, essentially as described by Saiki et al., Science 35230. 1985, pp. 1350-1354. After amplification, the amplified DNA may be digested with the appropriate restriction endonuclease and subjected to agarose gel electrophoresis. The restriction pattern obtained may be analysed, e.g. by staining with ethidium bromide and visualising bands in the gel by means of UV light. As a control, wild-type DNA encoding IRS-1 (i.e. not containing the mutation) may be subjected to the same procedure, and the restriction patterns may be compared. In the method of the invention, the sample is preferably analysed for a mutation located at a site where amino acid substitution interferes with signal transduction through IRS-1. A specific example of such a mutation is the mutation of G to A in the first position of codon 972 of the gene encoding IRS- 1. This mutation results in a new restriction endonuclease cleavage site 5'-C C A/T G G-3 1 3'-G G T/A C C-3 1 in the mutant DNA sequence coding for IRS-1. An example of a suitable restriction endonuclease is BstNl. A further embodiment of the method of the invention is an adaptation of the method described by U. Landegren et al., Science 241, 1988, pp. 1077-1080, which involves the ligation of adjacent oligonucleotides on a complementary target DNA molecule. Ligation will occur at the junction of the two oligonucleotides if the nucleotides are correctly base paired. In a still further embodiment of the present method, the DNA isolated from the sample may be amplified using oligonucleotide primers corresponding to segments of the gene coding for IRS-1. The amplified DNA may then be analysed by hybridisation with a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a mutation of at least one nucleotide, which mutation corresponds to the mutation the presence of which in the gene encoding IRS-1 is to be detected. As a control, the amplified DNA may furthermore be hybridised with a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the wild-type gene encoding IRS-1. This 5 procedure is, for instance, described by DiLella et al., Lancet 1 , 1988, pp. 497-499. Another PCR-based method which may be used in the present invention is the allele-specific PCR method described by R. Saiki et al., Nature 324 , 1986, pp. 163-166, or D.Y. Wu et al., Proc. Natl. Acad. Sci. USA 86. 1989, pp. 2757- 102760, which uses primers specific for the mutation in the IRS-1 gene. Other methods of detecting mutations in DNA are reviewed in U. Landegren, GATA 9 . , 1992, pp. 3-8. A currently preferred method of detecting mutations is by single stranded conformation 15 polymorphism (SSCP) analysis substantially as described by Orita et al., Proc. Natl. Acad. Sci. USA 86, 1989, pp. 2766- 2770, or Orita et al., Genomics 5_, 1989, pp. 874-879. The label substance with which the probe is labelled is preferably selected from the group consisting of enzymes, 20 coloured or fluorescent substances, or radioactive isotopes. Examples of enzymes useful as label substances are peroxidases (such as horseradish peroxidase) , phosphatases (such as acid or alkaline phosphatase) , β-galactosidase, urease, glucose oxidase, carbonic anhydrase, acetylcholinesterase, glu- 25 coamylase, lysozyme, malate dehydrogenase, glucose-6-phosphate dehydrogenase, β-glucosidase, proteases, pyruvate de- carboxylase, esterases, luciferase, etc. Enzymes are not in themselves detectable but must be combined with a substrate to catalyse a reaction the end product of 30 which is detectable. Examples of substrates which may be em¬ ployed in the method according to the invention include hydrogen peroxide/tetramethylbenzidine or chloronaphthole or o- phenylenediamine or 3-(p-hydroxyphenyl) propionic acid or luminol, indoxyl phosphate, p-nitrophenylphosphate, nitrophenyl galactose, 4-methyl umbelliferyl-D-galactopyranoside, or luciferin. Alternatively, the label substance may comprise coloured or fluorescent substances, including gold particles, coloured or fluorescent latex particles, dye particles, fluorescein, phycoerythrin or phycocyanin. In a particularly favoured embodiment, the probe is labelled with a radioactive isotope. Radioactive isotopes which may be used for the present purpose may be selected from 1-125, 1-131, In-Ill, H-3, P-32, C-14 or S-35. The radioactivity emitted by these isotopes may be measured in a beta- or gamma-counter or by a scintillation camera in a manner known per se. For use in the present method, the invention further relates to a test kit for detecting the presence of a mutation in the gene encoding IRS-1, the kit comprising (a) a restriction endonuclease which cleaves DNA at the site of the mutation, (b) a first DNA sequence corresponding to at least part of the wild-type gene encoding IRS-1, and/or (c) a second DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a mutation of at least one nucleotide, which mutation corresponds to the mutation the presence of which in the gene encoding IRS-1 is to be detected. The first DNA sequence may, for instance, be obtained from genomic DNA or cDNA encoding IRS-1 obtained from a healthy subject. The second DNA sequence may conveniently be a DNA construct according to the invention. For use in the present method, the invention further relates to a test kit for detecting the presence of a mutation in the gene encoding IRS-1, the kit comprising (a) means for amplifying DNA, and (b) a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a mutation of at least one nucleotide, which mutation corresponds to the mutation the presence of which in the gene encoding IRS-1 is to be detected. Appropriate means for amplifying DNA (typically genomic DNA isolated from the biological sample) include, for instance, oligonucleotide primers, appropriate buffers and a thermostable DNA polymerase. The invention is further illustrated in the following example which is not intended in any way to limit the scope of the invention as claimed. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows mutation screening using single stranded conformation polymorphism technique (SSCP) of nucleotideε 3338- 3600 of the human insulin receptor substrate 1 (IRS-1 gene) . The fragment was PCR-a plified from genomic DNA using specific oligonucleotide primers and 32 P-labeled and subjected to nondenaturing gel electrophoresis as described in Methods. The autoradiogram shows the migration profiles of single stranded (ss DNA) as well as double stranded DNA (ds DNA) . Lane 3 depicts the migration profile of an individual who is heterozygous (He) for the glycine 972 mutation. Lanes 1 and 2 show the migration profile for the corresponding wild type (Wt) . Fig. 2 shows direct nucleotide sequencing of a part of the 3338-3600 base pair fragment of IRS-1. The sequencing was performed on the noncodinq strand (c.f. Table 3). Upper panel shows the wild type sequence whereas lower panel depicts the nucleotide sequence from an individual who is heterozygous for a single base substitution in the coding strand at nucleotide position 3494 as indicated by an arrow, (G → A) (c.f. Table 3) . The base substitution in codon 972 caused a substitution of glycine with arginine. EXAMPLES Example 1 Subjects A total of 86 NIDDM patients and 76 control subjects were included in the protocol. All study participants were unrelated Danish Caucasians and their clinical characteristics are given in Table 1 and 2. The control subjects had normal fasting plasma glucose levels and no family history of known diabetes. Patients with NIDDM, as defined by the National Diabetes Data Group (18) , were recruited consecutively and unselected from the outpatient clinic at Steno Diabetes Center. All NIDDM patients were treated with diet, oral hypoglycemic drugs, or both. None of the participants in the study suffered from liver or kidney diseases as evaluated by clinical and standard laboratory examinations, and no subject was taking any other medication known to influence pancreatic 3-cell function or energy metabolism. Before participation, the purpose and risks of the study were carefully explained to all volunteers and their informed consent was obtained. The protocol was approved by the local Ethical Committee of Copenhagen and was in accordance with the Helsinki declaration. Euglycemic, Hyperinsulinemic Clamp NIDDM patients and 19 glucose-tolerant healthy control subjects were examined using a euglycemic, hyperinsulinemic clamp. The experiments were undertaken in the fasting state between 08.00 and 15.00 after a 10 h overnight fast. Each clamp comprised a 2 h basal period followed by a 4 h hyperinsulinemic glucose clamp. Details of the clamp technique have been described previously (19) . To assess total peripheral glucose uptake, (3- 3 H) glucose was infused throughout the study period. In the control subjects, (3- 3 H) glucose was administered as a primed (25-μCi) continuous (0.25-μCi/min) infusion, whereas in the NIDDM subjects, the priming was increased in proportion to the increase in fasting plasma glucose concentration; the continuous infusion of labeled glucose was the same as in the control subjects (0.25 μCi/min) . The clamp was performed by continuous infusion of 2 mU insulin x kg "1 x min "1 (Actrapid, Novo Nordisk, Denmark) , and euglycemia was maintained by a variable infusion of 20% glucose at a rate determined by the measurement of plasma glucose levels at 5 to 10 min invervals. Total glucose disposal rate was calculated from the plasma concentrations of (3- 3 H) glucose and plasma glucose with Steele's non-steady state equations (20) . In these calculations, the distribution volume of glucose was taken as 200 ml/kg body weight and the pool fraction as 0.65. At the highest steady state plasma insulin level, where the hepatic glucose production is presumed to be nil, glucose infusion rates were used to calculate glucose disposal. Total peripheral glucose uptake was corrected for urinary glucose loss. Preparation and Amplification of Genomic DNA Genomic DNA was isolated from human leucocyte nuclei isolated from whole blood by protein kinase K digestion followed by phenol extraction on a Applied Biosystems 341 Nucleic Acid Purification System. A primary 50 μl PCR reaction was carried out with 0,3 μg of genomic DNA. The assay conditions were: 10 mM Tris-HCl (pH 9.0), 50 mM KC1, 1.5 mM MgCl 2 , 0.1% Triton X- 100, 0.2 mM dNTP's, 0.2 μM of each oligonucleotide primer and 1.25 u Taq DNA polymerase (Promega, Madison, Wisconsin). Specific oligonucleotide primers for the human IRS-1 gene (4), 20-25 mers and 2 G's or C's at the 3' end, were synthezised on an Applied Biosystems 394 DNA/RNA syntheziser (Applied Biosystems Inc., Foster City, CA) and eluted on a NAB-10 column (Pharmacia P-L Biochemicals Inc, Milwaukee, Wisconsin) and used without further purification. 5 The nucleotide sequences of the DNA primers used for the polymerase chain reactions were as follows: GCTCAGCGTTGGTGGTGGCGGTGG3 ' 577 CGACGAAGTTGTAGTTGTTCGCCCG5 » 807 GAAGTGGCGGCACAAGTCGAGCGC3 ' 756 CGAGGCCGGAACCACTCCGACC5 » 1020 ACCGTGCTAAGGGCCACCACGACG3 ' 947 CCTCCGTCGCCGGCACCACGA5 • 1200 TCTACCGCCTTTGCCTGACCAGC3 • 1150 CGGTCAGGAGCAGGTTGACG5• 1411 ACCATCCTGGAGGCCATGCGG3 ' 1357 GGTCGGAGCCACCTGCCGTCGGGA5 • 1621 CAGGCTCCTTCCGTGTCCGCG3 • 1565 GGGTGCCGCTAGATCACGAAG5• 1827 CTGTCGTCCAGTAGCACCAGTGG3 • 1779 GGGACTGGCGGGGGTTGCCAG5• 2037 GCGGTGAGGAGGAGCTAAGC3 • 1932 GGGCAGGGTCAGGAGTCACCG5' 2230 AGAGAACTCACTCGGCAGGC3 ' 2170 GGTGTGCCTACTACCGATGTACGG5' 2424 CCCCTTGGAGCGTCGGGGG3 • 2371 GGACTGAATCCTCCACCGGGGTCG5 • 2623 CAGAGAGTGGACCCCAATGG3 ' 2566 CCTGAGGTTGTGGTCGTCGG5• 2819 TCTTGCCTCACCCCAAACCC3 • 3150 CGAGACCAGCGGAAGAGATA5 • 2983 GAGCCGGAGGAGGGTGCCCG3 ' 2938 GGTTCCGGTCGTGGAATGGA5' 3199 CAGACCAATAGCCGCCTGGC3 • 3150 CCGTGACTCCTCATGTACTT5 ! 3411 CTTCTGTCAGGTGTCCATCC3 ' 3358 CGATGCACCTGTGGAGCGGT5' 3601 GGGCAGTGCCCAGCAGCCGG3 ' 3541 CGACGGGTGAGCAGGGACGACC5• 3764 CCTCAGCAGCCTCTGCTTCC3 • 3712 CGTCGTCATCCCCCGCCACC5' 3969 CCACACCCAGTGCCACCCGG3 • 3919 CCTGAAGTTTGTCACGGGAG5• 4160 GAGCCAGCCAAACTGTGTGG3 ' 4086 CCTGTAGTGTCGTCCAGCAA5' 4339 The mixture was overlaid with 40 μl of mineral oil and after 20 initial denaturation at 95°C for 3 min, the samples were subjected to 35 cycles of amplification: annealing at 60°C for 1 min, extension at 72°C for 2 min and denaturation at 94°C for 1 min. In these primary PCR reactions, fragments of 800-900 bp, were amplified. A secondary PCR reaction was performed with 1 25 μl of a 1:10 diluted primary PCR product as template. The amplification conditions were as described above, except that (α- 3 P)dCTP (Amersham International, Buckinghamshire, UK) was added. Each fragment amplified during secondary PCR had a size of 250-285 bp. Single Stranded Conformation Polymorphism (SSCP) Analysis In the primary mutation screening, SSCP analysis (according to the method of Orita et al., Genomics 5 , 1989, pp. 874-879) of the entire coding region of IRS-1 was performed on genomic DNA from 19 insulin resistant NIDDM patients and 5 control subjects (Table 1) . In all cases, 2 μl of a secondary PCR product was combined with 8 μl of a sequencing stop solution. One μl was loaded unheated to identify double-stranded products and after heating at 94°C for 5 min, 2 μl was loaded to the same wells on a 38 x 31 x 0,03 cm 5% polyacrylamid gel (49:1, acrylamid:bisacrylamid) in 90 mM Tris-borate, 2,5 mM EDTA, with 1% or 5% glycerol, respectively. In each patient SSCP analysis was undertaken at 2 different experimental conditions: electrophoresis was carried out with 1% glycerol at 35 W constant power for 4-5 h at 4°C by placing gel, buffer and electrophoresis apparatus at 4°C overnight, and with 5% glycerol at 65 W constant power for 2-3 hours at 25°C (21) . The gels were transferred to 3 MM filter paper, covered with a plastic wrap and autoradiographed at -80°C with intensifying screens for 2-10 h. Gels contained 2 lanes with a known plasmid mutation and the corresponding wild type fragment as positive controls. In our laboratory the ability to detect known plasmid mutations (single base substitutions, small insertions, or small deletions) is 80-90% (22) . Synthesis of Single-Stranded DNA and Direct Nucleotide Sequencing Single stranded DNA for sequencing was generated using biotinylated oligonucleotide primers and streptavidin-coated magnetic beads (available from Dynal AS, Oslo, Norway). Products were precipitated with ammoniumacetate and isopropanol and resuspended in appropiate volumes of water. Sequencing using the AutoRead Sequencing Kit (Pharmacia, Uppsala, Sweden) and Fluore-dATP was analysed on an automated laser fluorescence DNA sequencer (Pharmacia, Uppsala, Sweden) . Direct Restriction Enzyme Digestion of PCR Products Restriction enzyme digestion was carried out in 15 μl reactions,- containing 10 μl precipitated secondary PCR product, 1,5 μl lOx NE buffer 2, 100 μg/ml bovine serum albumin and 10 u of the restriction enzyme BstN 1 (New England BioLabs Inc., Beverly, MA). The fragments were analyzed on a 4.5% high solution agarose gel and visualized after staining with ethidium bromide. Synthesis of cDNA Percutaneous muscle biopsies (- 500 mg) were obtained under local anesthesia from the vastus lateralis muscle of the thigh. Muscle samples were blotted to remove blood and connective and adipose tissue and were within 30 sec frozen in liquid N 2 and stored at -80°C until assayed. Total RNA was isolated from muscle biopsies as described (23) . cDNA was synthesized in 25 μl volumes containing 1 μg of total RNA, 0.2 mM deoxynucleoside triphosphates, 40 u RNasin (Promega, Madison, Wisconsin), 0.625 μg oligo (dT) 18 , 400 u Moloney Murine Leukaemia Virus Reverse Transcriptase (Life Technologies Inc., Grand Island, NY), 50 mM Tris-HCl (pH 8.3), 75 mM KC1, 3 mM MgCl 2 and 10 mM DTT. The reactions were performed at 37°C for 1 hour, followed by enzyme inactivation by incubation for 10 min at 95°C. SSCP was performed on cDNA as described for genomic DNA. Other Assays Plasma for analysis of chemical quantities was drawn from all study participants in the morning after 10 h of overnight fast. Plasma glucose was measured in duplicate by a hexokinase method. Tritiated glucose in plasma was determined as described (24). HbA lc was measured using a HPLC method (normal range 4.1- 6.4%). Plasma insulin and C-peptide levels were analyzed by radioimmuno-assays (25,26). Statistical Analysis Data in text and tables are given as means ± SE. For comparisons Mann-Whitney's test for unpaired data was applied. Primary Screening for Mutations in the IRS-1 Gene In 19 overlapping fragments, each consisting of 250-285 bp, the entire coding region of the IRS-1 gene was analyzed using genomic DNA from 19 NIDDM patients and 5 control subjects. Compared with matched control subjects the NIDDM patients were as a group hyperinsulinemic (p < 0.02) and were characterized by impaired insulin stimulated glucose disposal to peripheral tissues (p <0.0001) (Table 1). SSCP scanning showed 3 different aberrant migration profiles. Subsequent nucleotide sequencing revealed one polymorphism at codon 805 (GCA → GCG (alanine) ) . Four of 19 NIDDM patients were heterozygous for this single base substitution which did not predict any change in the amino acid sequence. Another silent mutation was detected at codon 894 (CCG → CCC (proline) ) . Only one of 19 NIDDM patients was heterozygous for this nucleotide base variation. However, at codon 972 SSCP analysis showed that three of 19 NIDDM patients were heterozygous for a mutation in which glycine (GGG) was substituted for arginine (AGG) (Figs 1 and 2) . The mutation was confirmed by sequencing of both DNA strands and by direct enzymatic digestion of PCR products with the restriction enzyme Bst Nl, for which a restriction site was created by the nucleotide substitution (data not shown) . None of the 5 control subjects, who primarily were SSCP scanned, showed evidence of polymorphisms. The glycine 972 mutation was located between 2 Tyr-Met-X-Met motifs in the IRS-1 gene (Table 3) . Subsequently, the codon 972 mutation, primarily identified on genomic DNA isolated from blood cells, was verified by studies of cDNA, synthesized from total RNA which was isolated from skeletal muscle biopsies. Secondary Screening for Glycine 972 Mutation Using SSCP molecular scanning and specific enzymatic digestion of primary PCR products further 67 NIDDM patients (Table 2) and 76 healthy control subjects were examined for the occurrence of the glycine 972 mutation. Seven of the 67 NIDDM patients were heterozygous for the mutation. Moreover, 3 of 76 healthy volunteers were also heterozygous carriers of the codon 972 mutation. All 3 control subjects who were positive for the mutation had a normal glucose response to an oral glucose challenge (data not shown) . Clinical Characterization of Individuals Carrying the Glycine 972 Mutation Table 1 shows the results obtained from the clinical investigations of the 3 glucose-tolerant controls who were positive for the glycine 972 mutation. Insulin-glucose clamp was performed in 2 of the 3 mutation carriers and the glucose disposal rates of these individuals were within the range of the 19 mutation-negative control subjects. However, interestingly also glucose- tolerant mutation carriers were characterized by relatively low values of fasting plasma insulin (decreased by 33-46%) and C-peptide (decreased by 25- 40%) , respectively, when compared with mean values obtained in mutation-negative healthy controls. Table 2 gives a summary of the phenotypical characteristics of the 10 NIDDM patients who are heterozygous carriers of the glycine 972 mutation in the IRS-1 gene when compared to 76 NIDDM patients who are negative for the same mutation. No significant differences were shown in age, known diabetes duration, body mass index, fasting levels of plasma glucose, HbA 1c and basal or insulin stimulated glucose disposal rates. However, fasting plasma levels of insulin and C-peptide were reduced by 44% (p < 0.05) and 37% (p < 0.02), respectively, in diabetics who were positive for the glycine 972 mutation when compared with mutation- negative diabetic subjects. Example 2 A random sample of 383 unrelated healthy young Caucasians (15- 32 years of age) was studied to determine whether the glycine 972 mutation confers insulin resistance. All individuals had their insulin sensitivity estimated using Bergman's minimal model (intravenous injections of glucose combined with tolbutamide) , and the occurrence of the glycine 972 mutation was determined by means of SSCP scanning (as described in Example 1) and restriction enzyme analysis of genomic DNA (as described in Example 1) . 35 subjects were found to carry the mutation. Those carriers of the glycine 972 mutation who had a body mass index (BMI) of more than 25 kg/m 2 (n=10, BMI=28.4 ± 0.9 kg/m 2 ) (mean ± standard error) had a two-fold lower insulin sensitivity and a significantly higher fasting serum level of C-peptide than the non-carriers with the same BMI (n=99, BMI=28.1 ± 0.3 kg/m 2 ). In contrast, there was no difference in the measured variables between the carriers and non-carriers of the mutation in subjects with a BMI of less than 25 kg/m 2 . In multivariate analysis adjusting for differences in V0 2 max, BMI, gender and age, the presence of the glycine 972 mutation within the group of obese subjects was negatively associated with insulin sensitivity (p < 0.04) and positively associated with fasting serum C-peptide (p < 0.09), fasting serum triglyceride (p < 0.02) and serum total cholesterol (p < 0.03). The results of the study show that in young obese subjects, the glycine 972 mutation is associated with whole-body insulin resistance and dyslipidemia. REFERENCES 1. Hitman GA, McCarthy MI. Genetics of non-insulin-dependent diabetes mellitus. Baillieres Clin Endocrinol Metab 1991; 5:455-476. 2. DeFronzo RA. The triumverate: /3-cell, muscle, liver: a collision responsible for NIDDM. Diabetes 1988; 37:667-687. 3. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 1988; 82:1151-1156. 4. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature (Lond ) 1991; 352:73-77. 5. Rothenberg P, Lane WS, Karasik A, Backer J, White MF, Kahn CR. Purification and partial sequence analysis of ppl85, the major cellular substrate of the insulin receptor tyrosine kinase. J Biol Chem 1991; 266:8302-8311. 6. Nishiyama M, Wands JR. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res 1992; 183:280-285. 7. Backer JM, Schroeder GG, Kahn CR, et al. Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J Biol Chem 1992; 267:1367-1364. 8. Myers Jr MG, Backer JM, Sun XJ, et al. IRS-1 activates phosphatidylinositol 3-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci USA 1992; 89:10350-10354. 9. Backer JM, Myers Jr MG, Shoelson SE, et al. Phosphatidylinositol 3-kinase is activated by association with IRS-1 during insulin stimulation. The EMBO Journal 1992; 11: 3469 - 3479. 5 10. Yonezawa K, Ueda H, Hara K, et al. Insulin-dependent formation of a complex containing an 85-kDa subunit of phosphatidylinositol 3-kinase and tyrosine-phosphorylated insulin receptor substrate 1. J Biol Chem 1992; 10267:25958-25966. 11. Folli F, Saad MJA, Backer JM, Kahn CR. Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact 15 rat. J Biol Chem 1992; 267:22171-22177. 12. Yonezawa K, Yokono K, Shii K, et al. In vitro association of phosphatidylinositol 3-kinase activity with the activated insulin receptor tyrosine kinase. J Biol Chem 1992; 20267:440-446. 13. Hayashi H, Kamohara S, Nishioka Y, et al. Insulin treatment stimulates the tyrosine phosphorylation of the α-type 85-kDa subunit of phosphatidylinositol 3-kinase in vivo. J Biol 25 Chem 1992; 267:22575-22580. 14. Sun XJ, Miralpeix M, Myers Jr MG, et al. Expression and function of IRS-1 in insulin signal transmission. J Biol Chem 1992; 267:22662-22672. 30 15. Shoelson SE, Chatterjee S, Chaudhuri M, White MF. YMXM motifs of IRS-1 define substrate specificity of the insulin receptor kinase. Proc Natl Acad Sci USA 1992; 89:2027-2031. 16. McClain DA, Maegawa H, Scott Thies R, Olefsky JM. Dissection of the growth versus metabolic effects of insulin 35 and insulin-like growth factor-I in transfected cells expressing kinase-defective human insulin receptors. J Biol Chem 1990; 265:1678-1682 17. Taylor SI, Cama A, Accili D. Molecular genetics of insulin resistant diabetes mellitus. J Clin Endocrinol Metab 1991; 5 73:1158-1163. 18. National Diabetes Data Group . Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-1057. 10 19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223. 15 20. Steele R. Influence of glucose loading and of injected insulin on hepatic glucose production. Ann NY Acad Sci 1959; 82:420-430. 21. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. 20 Detections of polymorphisms of human DNA by gel electrophoresis as single-stranded conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-2770. 22. Vestergaard H, Bjørbaek C, Andersen PH, Bak JF, Pedersen O. Impaired expression of glycogen synthase mRNA in skeletal 25 muscle of NIDDM patients. Diabetes 1991; 40:1740-1745. 23. Chomczynski P, Sachhi N. Single-step method of RNA isolation by acid guanidiniu thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159. 3024. Hother-Nielsen 0, Schmitz 0, Bak JF, Beck-Nielsen H. Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type I (insulin-dependent) diabetes. Diabetologia 1987; 30:834-840. 25. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8:260-266. 26. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11:541-548. 27. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr 185,000 protein in intact cells. Nature (Lond ) 1985; 318:183-186. 28. White MF, Stegmann EW, Dull TJ, Ullrich A, Kahn CR. Characterization of an endogenous substrate of the insulin receptor in cultured cells. J Biol Chem 1987; 262:9769-9777. TABLE 1 Fhenotypical characterization of 19 NIDDM patients who were examined w the IRS-1 gene: coirparisons to 19 matched controls without detected IRS-1 m controls in whom glycine 972 was substituted with arginine N Age (F:M) (yr) NIDEM Mean 6/13 54 29 7.9 10.4 95 0.92 CcO ± SE 2 1 0.5 0.9 13 0.09 CD CONTROL (noncarriers of mutation) Mean 7/12 50 28 5.4* 5.5* 60+ 0.67§ ± SE 2 1 0.1 0.1 6 0.04 m CO CONTROL (carriers of mutation) No.l F 50 27 4.7 5.1 32 0.40 m No.2 M 64 23 5.6 6.0 40 0.51 -m» No.3 M 66 23 6.0 5.9 34 0.42 Plasma levels of glucose, insulin and C-peptide were measured in the fasting the glucose disposal rate (mg/π^/min) in the fasting state (basal) in th euglycemic and hyperinsulinemic clamp (insulin) with steady state plasma insuli 30 min of the clamp of 1165 ± 71 pM in NIDDM patients and 1034 ± 56 pM in cont glycine 972 mutation. In the 3 glucose-tolerant mutation carriers the steady stat pM (subject no.l) and 1008 pM (subject no.2), respectively. ND = not determin vs. NIDDM; §P< 0.03 vs. NIDEM. TABLE 2 Characteristics of 10 NIDDM patients who are carriers of the glycine 972 -> arginine mutation in the IRS-1 gene: comparisons to NIDDM patients who are noncarriers of the mutation +Mutation -Mutation N (F/M) /ϊ 30/46 Age (yr) 52 ± 2 54 ± 1 Body Mass Index (kg/m 2 ) 29 ± 2 30 ± 1 Known duration of diabetes (yr) 5 ± 1 4 ± 1 HbA 1c (%) 8.6 ± 0.6 8.0 ± 0.2 Plasma glucose (mM) 12.4 ± 1.1 11.7 ± 0.5 Plasma insulin (pM) 53 ± 10 94 ± 8 * Plasma C-peptide (nM) 0.49 ± 0.06 0.78 ± 0.05 + M-value (basal) 86 ± 5 91 ± 3 M-value (insulin) 286 ± 29 265 ± 16 Value are means ± SE. Plasma concentrations of glucose, insulin and C-peptide were measured in the fasting state in the morning. M-value is the glucose disposal rate (mg/m 2 /min) in the fasting state (basal) in the morning and after 4 hours of euglycemic and hyperinsulinemic clamp (insulin) with steady state plasma insulin concentrations during the last 30 min of the clamp of 980 ± 57 pM in NIDDM patients who were carriers of the glycine 972 mutation and 1153 ± 34 pM in NIDDM patients who were noncarriers, respectively. *P< 0.05; +P< 0.02. Table 3 . Partial nucleotide (3392-3562) and amino acid (938-994) sequence of the published human insulin receptor substrate 1 (IRS-1) . The glycine to arginine mutation is located at codon 972 (shown in bold) . Two YMXM motifs which are putative recognition sites for insulin signal transmission proteins carrying src homology-2 domains are underlined. bp3392 coding 5 ' - _X3CACTGAGGAGTACATGAAGATGGACCTGG^ noncoding 3 ' A GAGAGCACTGGGGTα_aGA_IGGGCAGACTGGα Arg GluSerTh_ι^lyValGlUMetGlyA_rg:i_eu^ 972 3562 Ile(_ysA_rcFPπ_mιrA_t tAla 994 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPKECANT: (A) NAME: Novo Nordisk A/S (B) SIREET: Novo Alle (C) CITY: Bagsvaerd (E) COUNTRY: Denmark (F) POSTAL CODE (ZIP) : 2880 (G) TELEPHONE: +45 4444 8888 (H) TELEFAX: +454449 3256 (I) TELEX: 37304 (ii) "TITLE OF INVENTION: Mutant DNA Encoding Insulin Receptor Substrate 1 (iii) NUMBER OF SEQUENCES: 2 (iv) COMEUIER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMEUIER: IBM PC cσπpatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFIWARE: Patentln Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6152 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOFOIOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 581..4309 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TGGΕAITTGG GCGGCTGCTG GCEGCGGGGA CTGTTGGAGG GTGGGAGGAG GCGAAGGAGG 60 AGGGAGAACC CCX3TGCAACG TIGGGACTTG GCAACCCGCC TCCCCCTGCC CAAGGAIATT 120 TAATΠGCCT CGGGAATOGC TGCTΓCCAGA GGGGAACΓCA GGAGGGAAGG GGGCGCGCGC lso TCCIGGAGGG GCACCGCAGG GACCCCCGAC TGTOGCCTCC CT_GTGCOGGA CTCCAGCCGG 240 GGCGACGAGA GATGCATCTT CX_κπCCTTCC TGGTGGCGGC GGCX3GCIGAG AGGAGACITG 300 GCTCTCGGAG GATCGGGGCT GCCCTCACCC CGGAOGCACT GCCTCCCOGC OGGGCGTGAA 360 GCGCCCGAAA ACTCCGGTCG GGCTCICTOC TGGGCTCAGC AGCTGCGTCC TCCTTCAGCT 420 GCCCCTCCCC GCGCGGGGGG CGGCGTGGAT TTCAGAGTCG GGGTITCTGC TGCCTCCAGC 480 CCTGm GCA TGTGCCGGGC CGCGGCGAGG AGCCTCCGCC CCCCACCCGG TTGTΓITTCG 540 GAGCCTCCCT CTGCTCAGCG TIGGTGGTGG CGGTGGCAGC ATG GCG AGC CCT COG 595 Met Ala Ser Pro Pro 1 5 GAG AGC GAT GGC TTC TOG GAC GTG CGC AAG GTG GGC TAC CTG CGC AAA 643 Glu Ser Asp Gly Ehe Ser Asp Val Arg Lys Val Gly Tyr Leu Arg Lys 10 15 20 CCC AAG AGC ATG CAC AAA CGC TTC TTC GTA CTG CGC GCG GCC AGC GAG 691 E>ro Lys Ser Met His Lys Arg Ene E*ιe Val Leu Arg Ala Ala Ser Glu 25 30 35 GCT GGG GGC COG GCG CGC CTC GAG TAC TAC GAG AAC GAG AAG AAG TGG 739 Ala Gly Gly Pro Ala Arg Leu Glu Tyr Tyr Glu Asn Glu Lys Lys Trp 40 45 50 CGG CAC AAG TOG AGC GCC CCC AAA CGC TCG ATC CCC CIT GAG AGC TGC 787 Arg His Lys Ser Ser Ala Pro Lys Arg Ser lie Pro Leu Glu Ser Cys 55 60 65 TTC AAC ATC AAC AAG CGG GCT GAC TCC AAG AAC AAG CAC CTG GTG GCT 835 Phe Asn lie Asn Lys Arg Ala Asp Ser Lys Asn Lys His Leu Val Ala 70 75 80 85 CTC TAC ACC CGG GAC GAG CAC TTT GCC ATC GCG GCG GAC AGC GAG GCC 883 Leu Tyr Thr Arg Asp Glu His Phe Ala lie Ala Ala Asp Ser Glu Ala 90 95 100 GAG CAA GAC AGC TGG TAC CAG GCT CTC CTA CAG CTG CAC AAC CGT GCT 931 Glu Gin Asp Ser Trp Tyr Gin Ala Leu Leu Gin Leu His Asn Arg Ala 105 110 115 AAG GGC CAC CAC GAC GGA GCT GCG GCC CTC GGG GCG GGA GGT GGT GGT 979 Lys Gly His His Asp Gly Ala Ala Ala Leu Gly Ala Gly Gly Gly Gly 120 125 130 GGG GGC AGC TGC AGC GGC AGC TCC GGC CIT GGT GAG GCT GGG GAG GAC 1027 Gly Gly Ser Cys Ser Gly Ser Ser Gly Leu Gly Glu Ala Gly Glu Asp 135 140 145 TTG AGC TAC GGT GAC GTG CCC CCA GGA CCC GCA TTC AAA GAG GTC TGG 1075 Leu Ser Tyr Gly Asp Val Pro Pro Gly Pro Ala He Lys Glu Val Trp 150 155 160 165 CAA GTG ATC CTG AAG CCC AAG GGC CTG GGT CAG ACA AAG AAC CTG AIT 1123 Gin Val lie Leu Lys Pro Lys Gly Leu Gly Gin Thr Lys Asn Lsu lie 170 175 180 GGT ATC TAC CGC C T TGC CTG ACC AGC AAG ACC ATC AGC TTC GTG AAG 1171 5 Gly lie Tyr Arg Leu Cys Lsu Thr Ser Lys Thr lie Ser Phe Val Lys 185 190 195 CTG AAC TOG GAG GCA GCG GCC GTG GTG CTG CAG CTG ATG AAC ATC AGG 1219 Leu Asn Ser Glu Ala Ala Ala Val Val Leu Gin Leu Met Asn He Arg 200 205 210 10 CGC TGT GGC CAC TOG GAA AAC TTC TTC TTC ATC GAG GTG GGC OGT TCT 1267 Arg Cys Gly His Ser Glu Asn Phe Fhe Fhe He Glu Val Gly Arg Ser 215 220 225 GCC GTG ACG GGG CCC GGG GAG TTC TGG ATG CAG GTG GAT GAC TCT GTG 1315 Ala Val Thr Gly Pro Gly Glu Phe Trp Met Gin Val Asp Asp Ser Val 15230 235 240 245 GTG GCC CAG AAC ATG CAC GAG ACC ATC CTG GAG GCC ATG CGG GCC ATG 1363 Val Ala Gin Asn Met His Glu Thr He Lsu Glu Ala Met Arg Ala Met 250 255 260 AGC GAT GAG TTC CGC CCT CGC AGC AAG AGC CAG TCC TOG TCC AAC TGC 1411 20 Ser Asp Glu Phe Arg Pro Arg Ser Lys Ser Gin Ser Ser Ser Asn Cys 265 270 275 TCT AAC CCC ATC AGC GTC CCC CTG CGC CGG CAC CAT CTC AAC AAT CCC 1459 Ser Asn ΕTo He Ser Val Pro Leu Arg Arg His His Leu Asn Asn Pro 280 285 290 25 COG CCC AGC CAG GTG GGG CTG ACC CGC CGA TCA CGC ACT GAG AGC ATC 1507 Pro Iτo Ser Gin Val Gly Leu Thr Arg Arg Ser Arg Thr Glu Ser He 295 300 305 ACC GCCACC TCC CCG GCCAGCATG GTG GGC GGG G (XAC5GC TCC T^ 1555 Thr Ala Thr Ser .Pro Ala Ser Met Val Gly Gly Lys E>ro Gly Ser Fhe 30310 315 320 325 CGT GTC CGC GCC TCC ACT GAC GGC GAA GGC ACC ATG TCC CGC CCA GCC 1603 Arg Val Arg Ala Ser Ser Asp Gly Glu Gly Thr Met Ser Arg Pro Ala 330 335 340 TOG GTG GAC GGC AGC CCT GTG ACT CCC AGC ACC AAC AGA ACC CAC GCC 1651 35 Ser Val Asp Gly Ser Pro Val Ser Pro Ser Thr Asn Arg Thr His Ala 345 350 355 CAC CGG CAT CGG GGC AGG GCC CGG CTG CAC CCC COG CTC AAC CAC AGC 1699 His Arg His Arg Gly Arg Ala Arg Leu His Pro Pro Leu Asn His Ser 360 365 370 40 CGC TCC ATC CCC ATG COG GCT TCC CGC TGC TCC CGT TOG GCC ACC AGC 1747 Arg Ser He Pro Met Pro Ala Ser Arg Cys Ser Arg Ser Ala Thr Ser 375 380 385 COG GTC ACT CTG TOG TCC ACT AGC ACC ACT GGC CAT GGC TCC ACC TCG 1795 Pro Val Ser Lsu Ser Ser Ser Ser Thr Ser Gly His Gly Ser Thr Ser 390 395 400 405 GATTCT CTCTTC CX2A <^G CXΞΑTCT A T GCT TOG GTG TCT GGT TCC CCC 1843 Asp Cys Leu Fhe Pro Arg Arg Ser Ser Ala Ser Val Ser Gly Ser Pro 410 415 420 AGC GAT GGC GGT TTC ATC TCC TOG GAT GAG TAT GGC TCC AGT CCC TGC 1891 Ser Asp Gly Gly Phe He Ser Ser Asp Glu Tyr Gly Ser Ser Fro Cys 425 430 435 GAT TTC CGG ACT TCC TTC CGC ACT GTC ACT COG GAT TCC CTG GGC CAC 1939 Asp Phe Arg Ser Ser Fhe Arg Ser Val Thr Pro Asp Ser Leu Gly His 440 445 450 ACC CCACCAGCC CGCGCTGAGGAGGAG CTA AGC AAC TAT ATC TGC ATG 1987 Thr Pro Pro Ala Arg Gly Glu Glu Glu Leu Ser Asn Tyr He Cys Met 455 460 465 GGT GGC AAG GGG CCC TCC ACC CTG ACC GCC CCC AAC GGT CAC TAC ATT 2035 Gly Gly Lys Gly Pro Ser Thr Lsu Thr Ala Iro Asn Gly His Tyr He 470 475 480 485 TTG TCT CGG GGT GGC AAT GGC CAC CGC TGC ACC CCA GGA ACA GGC TIG 2083 Leu Ser Arg Gly Gly Asn Gly His Arg Cys Thr Pro Gly Thr Gly Lsu 490 495 500 GGC ACG ACT CCA GCC TTG GCT GGG GAT GAA GCA GCC AGT GCT GCA GAT 2131 Gly Thr Ser E>ro Ala Leu Ala Gly Asp Glu Ala Ala Ser Ala Ala Asp 505 510 515 CTG GAT AAT CGG TTC CGA AAG AGA ACT CAC TCG GCA GGC ACA TCC CCT 2179 Leu Asp Asn Arg Fhe Arg Lys Arg Thr His Ser Ala Gly Thr Ser E>ro 520 525 530 ACC ATT ACC CAC CAG AAG ACC COG TCC CAG TCC TCA GTG GCT TCC ATT 2227 Thr He Thr His Gin Lys Thr Pro Ser Gin Ser Ser Val Ala Ser He 535 540 545 GAG GAG TAC ACA GAG ATG ATG CCT GCC TAC CCA CCA GGA GGT GGC AGT 2275 Glu Glu Tyr Thr Glu Met Met Pro Ala Tyr Pro Pro Gly Gly Gly Ser 550 555 560 565 GGA GGC CGA CTG COG GGA CAC AGG CAC TCC GCC TTC GTG CCC ACC CGC 2323 Gly Gly Arg Leu Pro Gly His Arg His Ser Ala Ehe Val E>ro Thr Arg 570 575 580 TCC TAC CCA GAG GAG GGT CTG GAA ATG CAC CCC TTG GAG CGT CGG GGG 2371 Ser Tyr Pro Glu Glu Gly Leu Glu Met His I^ro l_eu Glu Arg Arg Gly 585 590 595 GGG CAC CAC CGC CCA GAC AGC TCC ACC CTC CAC ACG GAT GAT GGC TAC 2419 Gly His His Arg I*ro Asp Ser Ser Thr Leu His Thr Asp Asp Gly Tyr 600 605 610 ATG CCC ATG TCC CCA GGG GTG GCC CCA GTG CCC ACT GGC CGA AAG GGC 2467 Met Pro Met Ser E o Gly Val Ala Pro Val E > ro Ser Gly Arg Lys Gly 615 620 625 AGT GGA GAC TAT ATG CCC ATG AGC CCC AAG AGC GTA TCT GCC CCA CAG 2515 Ser Gly Asp Tyr Met Pro Met Ser Pro Lys Ser Val Ser Ala Pro Gin 630 635 640 645 CAG ATC ATC AAT CCC ATC AGA CGC CAT CCC CAG AGA GTG GAC CCC AAT 2563 Gin He He Asn E>ro He Arg Arg His Pro Gin Arg Val Asp PΪX> Asn 650 655 660 GGC TAC ATG ATG ATG TCC CCC AGC GCT GGC TGC TCT CCT GAC ATT GGA 2611 Gly Tyr Met Met Met Ser Pro Ser Gly Gly Cys Ser E>ro Asp He Gly 665 670 675 GGT GGC CCC AGC AGC AGC AGC AGC AGC AGC AAC GCC GTC CCT TCC GGG 2659 Gly Gly Pro Ser Ser Ser Ser Ser Ser Ser Asn Ala Val Pro Ser Gly 680 685 690 ACC AGC TAT GGA AAG CTG TGG ACA AAC GGG GTA GGG GGC CAC CAC TCT 2707 Thr Ser Tyr Gly Lys Leu Trp Thr Asn Gly Val Gly Gly His His Ser 695 700 705 CAT GTC TTG CCT CAC CCC AAA CCC CCA GTG GAG AGC AGC GCT GGT AAG 2755 His Val Leu Pro His Pro Lys Pro Pro Val Glu Ser Ser Gly Gly Lys 710 715 720 725 CTC TTA CCT TGC ACA GCT GAC TAC ATG AAC ATG TCA CCA GTG GGG GAC 2803 Leu Leu E>ro Cys Thr Gly Asp Tyr Met Asn Met Ser Pro Val Gly Asp 730 735 740 TCC AAC ACC AGC AGC CCC TCC GAC TGC TAC TAC GGC CCT GAG GAC CCC 2851 Ser Asn Thr Ser Ser Pro Ser Asp Cys Tyr Tyr Gly E>ro Glu Asp Pro 745 750 755 CAG CAC AAG CCA CTC CTC TCC TAC TAC TCA TTG CCA AGA TCC TTT AAG 2899 Gin His Lys Ero Val Leu Ser Tyr Tyr Ser Leu Fro Arg Ser Ehe Lys 760 765 770 CAC ACC CAG CGC CCC GGG GAG COG GAG GAG GGT GCC CGG CAT CAG CAC 2947 His Thr Gin Arg Pro Gly Glu Pro Glu Glu Gly Ala Arg His Gin His 775 780 785 CTC CGC C T TCC ACT AGC TCT GCT GGC C T CTC TAT GCT GCA ACA GCA 2995 Leu Arg Leu Ser Thr Ser Ser Gly Gly Lsu Leu Tyr Ala Ala Thr Ala 790 795 800 805 GAT GAT TCT TCC TCT TCC ACC AGC AGC GAC AGC CTG GGT GGG GGA TAC 3043 Asp Asp Ser Ser Ser Ser Thr Ser Ser Asp Ser Lsu Gly Gly Gly Tyr 810 • • 815 820 TGC GGG GCT AGG CTG GAG CCC AGC CTT CCA CAT CCC CAC CAT CAG GTT 3091 Cys Gly Ala Arg Lsu Glu Pro Ser Lsu Pro His E>ro His His Gin Val 825 830 835 CTG CAG CCC CAT CTG CCT CGA AAG GTG GAC ACA GCT GCT CAG ACC AAT 3139 Leu Gin Pro His Lsu Pro Arg Lys Val Asp Thr Ala Ala Gin Thr Asn 840 845 850 AC ∞C CTG GCC CnS CCCACG GG CTG TOC CTG GGG GAT CCC G 3187 Ser Arg Leu Ala Arg Pro Thr Arg Leu Ser Lu Gly Asp Pro Lys Ala 855 860 865 AGC ACC TTA CCT CGG GCC α_ΑGAG CAG ΑG CΑG α^ <^G CAG ( C 3235 Ser Thr Leu Pro Arg Ala Arg Glu Gin Gin Gin Gin Gin Gin Pro Leu 870 875 880 885 CTG CAC CCT CCA GAG CCC AAG AGC COG GGG GAA TAT GTC AAT ATT GAA 3283 Leu His Iro E>ro Glu Ero Lys Ser I>ro Gly Glu Tyr Val Asn He Glu 890 895 900 TTT GGG AGT GAT CAG TCT GGC TAC TTG TCT GGC COG GTG GCT TTC CAC 3331 Fhe Gly Ser Asp Gin Ser Gly Tyr Leu Ser Gly E>ro Val Ala Fhe His 905 910 915 AGC TCA CCT TCT GTC AGG TCT CCA TCC CAG CTC CAG CCA GCT CCC AGA 3379 Ser Ser Pro Ser Val Arg Cys Pro Ser Gin Leu Gin E Ό Ala E>ro Arg 920 925 930 GAG GAA GAG ACT GGC ACT GAG GAG TAC ATG AAG ATG GAC CTG GGG COG 3427 Glu Glu Glu Thr Gly Thr Glu Glu Tyr Met Lys Met Asp Leu Gly E Ό 935 940 945 GGC CGG AGG GCA GCC TGG CAG GAG AGC ACT GGG GTC GAG ATG GGC AGA 3475 Gly Arg Arg Ala Ala Trp Gin Glu Ser Thr Gly Val Glu Met Gly Arg 950 955 960 965 CTG GGC CXT GCA CCT CCCAGG GCT GCT AGC ATT TGC AGG CCT ACC CGG 3523 Lsu Gly Pro Ala Pro Pro Arg Ala Ala Ser He Cys Arg Pro Thr Arg 970 975 980 GCA GTG CCC AGC AGC CGG GCT GAC TAC ATG ACC ATG CAG ATG AGT TCT 3571 Ala Val E>ro Ser Ser Arg Gly Asp Tyr Met Thr Met Gin Met Ser Cys 985 990 995 CCC CGT CAG AGC TAC GTG GAC ACC TOG CCA GCT GCC CCT GTA AGC TAT 3619 Pro Arg Gin Ser Tyr Val Asp Thr Ser Pro Ala Ala Pro Val Ser Tyr 1000 1005 1010 GCT GAC ATG CGA ACA GGC A T GCT GCA GAG GAG GTG AGC CTG CCC AGG 3667 Ala Asp Met Arg Thr Gly He Ala Ala Glu Glu Val Ser Leu Pro Arg 1015 1020 1025 GCC ACC ATG GCT GCT GCC TCC TCA TCC TCA GCA GCC TCT GCT TCC COG 3715 Ala Thr Met Ala Ala Ala Ser Ser Ser Ser Ala Ala Ser Ala Ser Pro 1030 1035 1040 1045 ACT GGG CCT CAA GGG GCA GCA GAG CTG GCT GCC CAC TCG TCC CTG CTG 3763 Thr Gly E>ro Gin Gly Ala Ala Glu Leu Ala Ala His Ser Ser Lsu Leu 1050 1055 1060 GGG GGC CCA CAA GGA CCT GGG GGC ATG AGC GCC TTC ACC CGG GTG AAC 3811 Gly Gly Pro Gin Gly Iτo Gly Gly Met Ser Ala Fhe Thr Arg Val Asn 1065 1070 1075 CTC ACT CCT AAC CGC AAC CAG ACT GCC AAA CTG ATC CCT GCA GAC CCA 3859 Leu Ser Pro Asn Arg Asn Gin Ser Ala Lys Val He Arg Ala Asp Pro 1080 1085 1090 CAA GGG TGC CGG OGG AGG CAT AGC TCC GAG ACT TTC TCC TCA ACA CCC 3907 Gin Gly Cys Arg Arg Arg His Ser Ser Glu Thr Fhe Ser Ser Thr Pro 1095 1100 1105 ACT GCC ACC CGG GTG GGC AAC ACA GTG CCC TTT GGA GCG GGG GCA GCA 3955 Ser Ala Thr Arg Val Gly Asn Thr Val Pro Fhe Gly Ala Gly Ala Ala 1110 1115 1120 1125 GTA GGG GGC GGT GGC GGT AGC AGC AGC AGC AGC GAG GAT GTG AAA CGC 4003 Val Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Glu Asp Val Lys Arg 1130 1135 1140 CAC AGC TCT GCT TCC TTT GAG AAT GTG TGG CTG AGG CCT GGG GAG CTT 4051 His Ser Ser Ala Ser Fhe Glu Asn Val Trp Leu Arg Pro Gly Glu Leu 1145 1150 1155 GGG GGA GCC CCC AAG GAG CCA GCC AAA CTG TCT GGG GCT GCT GGG GCT 4099 Gly Gly Ala Pro Lys Glu .Pro Ala Lys Leu Cys Gly Ala Ala Gly Gly 1160 1165 1170 TTG GAG AAT GCT CTT AAC TAC ATA GAC CTG GAT TTG GTC AAG GAC TTC 4147 Leu Glu Asn Gly Leu Asn Tyr He Asp Leu Asp Leu Val Lys Asp Fhe 1175 1180 1185 AAA CAG TGC CCT CAG GAG TGC ACC CCT GAA CCG CAG CCT CCC CCA CCC 4195 Lys Gin Cys Pro Gin Glu Cys Thr Pro Glu Pro Gin Pro Fro Fro Pro 1190 1195 1200 1205 (XA CCC CCT Off O^ CCC CTG GGC AGC GCT GAG AGC AGC TCC ACC CGC 4243 Pro Pro Pro His Gin Pro Leu Gly Ser Gly Glu Ser Ser Ser Thr Arg 1210 1215 1220 CGC TCA ACT GAG GAT TTA AGC GCC TAT GCC AGC ATC ACT TTC CAG AAG 4291 Arg Ser Ser Glu Asp Leu Ser Ala Tyr Ala Ser He Ser Fhe Gin Lys 1225 1230 1235 CAG CCA GAG GAC CCT CAG TAGCTCAACT GGACATCACA GCAGGTOGTT 4339 Gin Pro Glu Asp Arg Gin 1240 TCATGGTGAC AAACTCAGAA GACAAAACTG CTTTTAACCT TGTCCTTGAA TKΠGTTCTT 4399 OGCCTCTGCC CCTTCCTGTT CTTTCCCACT GCTTCCTCAG GGAGAATGCA CTIACAΪTCT 4459 CAGGGCAIAC AAGATGCTCA CCCACACTGA CAITGGCAGA GACTCAAACA AACATGTAGG 4519 AGCAGCCACA GGAGGGCTTT TTCCTTTGAG GAATTCCCAA GTGAAGTAGT TACTGCACTA 4579 TTΓΓTAAACA TATATCCTAT GOCAGTΓCTG CX_Π_TΓTGTAG AG ICCΓCCG TAAGAAGCTT 4639 GATITGTTTG TTGAAGTTTT CTTTTCACTA TAIAITTAGG TCAGCCCCTG GAAGGACACT 4699 TCTACAAAAA A CCCGTTA ACACAGGGGC TA CCCTTC CITATCTCAA ACIMCTTAA 4759 TAGTTICTGG GAGCCCTTAA GGC_aX__ATCIT ATCAAGTTGT TOICTGTACT TITGITCTGT 4819 GAITTCAIAA TACTAGGGCA ACAIAAACAG CAGOGGGAAG CAITGAITTC TATTCATCCT 4879 GCCCTAAAAA GATCAGGAGT AAGAGCTTTT TAGAAATATG TATTIAGAGA GAACTACCTA 4939 TCTAITTTGT GATOTCTCAA GAAAGTAATT ATGGGTGACG TTCTCCTTTT GTTCATGTAC 4999 CAGGAITTCT GAAATATTAT TCACACAACC GACCCACCAT CCCAOGGGCC TGGCCTCTCT 5059 TGTACAGGAT ATGCAGGAAA CICTGTATCT GTCTGGGACC O^TTAITAAG AGTTATGGGA 5119 GTTCATCCTA GGATGTCTGC CTTATAGTTA TCTCTICTTC TTGCACTGAG ACAITACAGA 5179 TΆTCATTTGG GGGCIACTAT ATATCTΓCTG TAAAATTACT TTTAITΓGTT GAAGAAGAAT 5239 GCATACTAAG TCAGGAACAT GCCITAATTT GTTITGTΓTT GCAAITGAGT AGAAGGGCTA 5299 AACTGTATCC CTCCACTTTT AGGGTTATTT GCCTGTGTGC CTTTAAGTTC AAAAGTAGAC 5359 ACCACAGTAA ATGCTGAAAG TTGGCTTTAG GTCTTCTGTG GCTAATGCCG TATTAAAAAT 5419 GAAAAACATT TGTGGTAGAA AITAGCCTGC CCTKCTTCT GTIGATCCTG TITTCTGGTG 5479 GTCATAATTG TGGCTAGAAG AGACTACACT TTGCAAATAA TGTGATGACT TGGCAATGCA 5539 GAAGTTTCCA GCAITTGGAA ACACTTTACT CTGACAAACT GATTATCITG TGAATTTTAT 5599 CI^IGCTCCA CAGAATGAGC TTTTAAAAGC ACTGA LTTTT CTTAATTTGT CTCCATTCAT 5659 AAGAAATTAA TCTGTGCCCT GGTTTCCTAT TGA^GGTAT TTAITTATCA TGTGTTCAIA 5719 GTLTlLTiAA TTCTGTITCC AATATTTGAT CCAIAIAATT CTCTATITTA TAAAGCAAGA 5779 AAAAGGTATA TGAACACTCA AATGAAGATT TTGGGTGATA TGTTACAAAA AGCATTTATT 5839 TGATCAGTAT TTACTTCAAC AITTAITTTC ATCATTCACT AGAAGAAAGA TTTAATTGTG 5899 TATATCAACA TCAGTAGTAC AAAICTIGTT AIATCAAATG ATCJ1TTT1GG GAGTTCAGAA 5959 TCCCTCAACA CTTTAAGCAT TTGTATTATA AACTGCCTCA TTGCTAAAAT AATGAGAATT 6019 TGAAGAAAAC CAGCCCAGCA GAACTAAAAT TTTGGTTTTA AAGGAGATAA AGAGAAIAAG 6079 TTITTCTTAC TTGTCATCTT AATTTGTTTA GGTTICTTTT TAIAGAGTAG AATAAATGAT 6139 GTTTGCTCTG AAG 6152 (2) INFORMATTON FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1243 amino acids (B) TYPE: amino acid (D) TOFOIOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Ala Ser Pro Pro Glu Ser Asp Gly Fhe Ser Asp Val Arg Lys Val 1 5 10 15 Gly Tyr Leu Arg Lys Pro Lys Ser Met His Lys Arg Phe Phe Val Leu 20 25 30 Arg Ala Ala Ser Glu Ala Gly Gly Pro Ala Arg Lsu Glu Tyr Tyr Glu 35 40 45 Asn Glu Lys Lys Trp Arg His Lys Ser Ser Ala Pro Lys Arg Ser He 50 55 60 Pro Leu Glu Ser Cys Fhe Asn He Asn Lys Arg Ala Asp Ser Lys Asn 65 70 75 80 Lys His Leu Val Ala Leu Tyr Thr Arg Asp Glu His Fhe Ala He Ala 85 90 95 Ala Asp Ser Glu Ala Glu Gin Asp Ser Trp Tyr Gin Ala Leu Leu Gin 100 105 110 Leu His Asn Arg Ala Lys Gly His His Asp Gly Ala Ala Ala Leu Gly 115 120 125 Ala Gly Gly Gly Gly Gly Gly Ser Cys Ser Gly Ser Ser Gly Leu Gly 130 135 140 Glu Ala Gly Glu Asp Leu Ser Tyr Gly Asp Val Pro Pro Gly Pro Ala 145 150 155 160 Fhe Lys Glu Val Trp Gin Val He Lsu Lys Pro Lys Gly Leu Gly Gin 165 170 175 Thr Lys Asn Leu He Gly He Tyr Arg Leu Cys Leu Thr Ser Lys Thr 180 185 190 He Ser Fhe Val Lys Leu Asn Ser Glu Ala Ala Ala Val Val Leu Gin 195 200 205 Leu Met Asn He Arg Arg Cys Gly His Ser Glu Asn Phe Fhe Phe He 210 215 220 Glu Val Gly Arg Ser Ala Val Thr Gly Pro Gly Glu Fhe Trp Met Gin 225 230 235 240 Val Asp Asp Ser Val Val Ala Gin Asn Met His Glu Thr He Leu Glu 245 250 255 Ala Met Arg Ala Met Ser Asp Glu Fhe Arg E>ro Arg Ser Lys Ser Gin 260 265 270 5 Ser Ser Ser Asn Cys Ser Asn Pro He Ser Val Pro Lsu Arg Arg His 275 280 285 His Leu Asn Asn I>ro Pro Pro Ser Gin Val Gly Lsu Thr Arg Arg Ser 290 295 300 Arg Thr Glu Ser He Thr Ala Thr Ser Pro Ala Ser Met Val Gly Gly 10305 310 315 320 Lys Pro Gly Ser Fhe Arg Val Arg Ala Ser Ser Asp Gly Glu Gly Thr 325 330 335 Met Ser Arg Iro Ala Ser Val Asp Gly Ser I>ro Val Ser Pro Ser Thr 340 345 350 15 Asn Arg Thr His Ala His Arg His Arg Gly Arg Ala Arg Leu His Ero 355 360 365 Pro Leu Asn His Ser Arg Ser He I>ro Met Pro Ala Ser Arg Cys Ser 370 375 380 Arg Ser Ala Thr Ser Ero Val Ser Lsu Ser Ser Ser Ser Thr Ser Gly 20385 390 395 400 His Gly Ser Thr Ser Asp Cys Leu Phe Pro Arg Arg Ser Ser Ala Ser 405 410 415 Val Ser Gly Ser Pro Ser Asp Gly Gly Fhe He Ser Ser Asp Glu Tyr 420 425 430 25 Gly Ser Ser Pro Cys Asp Fhe Arg Ser Ser Fhe Arg Ser Val Thr .Pro 435 440 445 Asp Ser Leu Gly His Thr Pro Pro Ala Arg Gly Glu Glu Glu Lsu Ser 450 455 460 Asn Tyr He Cys Met Gly Gly Lys Gly Pro Ser Thr Leu Thr Ala Pro 30465 470 475 480 Asn Gly His Tyr He Leu Ser Arg Gly Gly Asn Gly His Arg Cys Thr 485 490 495 .Pro Gly Thr Gly Lsu Gly Thr Ser Pro Ala Leu Ala Gly Asp Glu Ala 500 505 510 35 Ala Ser Ala Ala Asp Lsu Asp Asn Arg Fhe Arg Lys Arg Thr His Ser 515 520 525 Ala Gly Thr Ser Pro Thr He Thr His Gin Lys Thr Ero Ser Gin Ser 530 535 540 Ser Val Ala Ser He Glu Glu Tyr Thr Glu Met Met Iro Ala Tyr Iro 545 550 555 560 Iro Gly Gly Gly Ser Gly Gly Arg Leu Pro Gly His Arg His Ser Ala 565 570 575 Fhe Val Fro Thr Arg Ser Tyr _Pro Glu Glu Gly Leu Glu Met His .Pro 580 585 590 Leu Glu Arg Arg Gly Gly His His Arg Ero Asp Ser Ser Thr Lsu His 595 600 605 Thr Asp Asp Gly Tyr Met Pro Met Ser Pro Gly Val Ala Pro Val Pro 610 615 620 Ser Gly Arg Lys Gly Ser Gly Asp Tyr Met Pro Met Ser Pro Lys Ser 625 630 635 640 Val Ser Ala Pro Gin Gin He He Asn Ero He Arg Arg His Pro Gin 645 650 655 Arg Val Asp Iro Asn Gly Tyr Met Met Met Ser Ero Ser Gly Gly Cys 660 665 670 Ser Pro Asp He Gly Gly Gly Pro Ser Ser Ser Ser Ser Ser Ser Asn 675 680 685 Ala Val Pro Ser Gly Thr Ser Tyr Gly Lys Leu Trp Thr Asn Gly Val 690 695 700 Gly Gly His His Ser His Val Leu Iro His Pro Lys Pro Pro Val Glu 705 710 715 720 Ser Ser Gly Gly Lys Leu Lsu Iro Cys Thr Gly Asp Tyr Met Asn Met 725 730 735 Ser Pro Val Gly Asp Ser Asn Thr Ser Ser Pro Ser Asp Cys Tyr Tyr 740 745 750 Gly Pro Glu Asp Ero Gin His Lys Pro Val Lsu Ser Tyr Tyr Ser Leu 755 760 765 Pro Arg Ser Fhe Lys His Thr Gin Arg Pro Gly Glu Ero Glu Glu Gly 770 775 780 Ala Arg His Gin His Leu Arg Leu Ser Thr Ser Ser Gly Gly Leu Leu 785 790 795 800 Tyr Ala Ala Thr Ala Asp Asp Ser Ser Ser Ser Thr Ser Ser Asp Ser 805 810 815 Leu Gly Gly Gly Tyr Cys Gly Ala Arg Leu Glu Iro Ser Lsu Iro His 820 825 830 Pro His His Gin Val Leu Gin Pro His Leu Fro Arg Lys Val Asp Thr 835 840 845 Ala Ala Gin Thr Asn Ser Arg Leu Ala Arg Pro Thr Arg Leu Ser Leu 850 855 860 Gly Asp Pro Lys Ala Ser Thr Leu Pro Arg Ala Arg Glu Gin Gin Gin 865 870 875 880 Gin Gin Gin Pro Leu Leu His Pro Pro Glu Pro Lys Ser Pro Gly Glu 885 890 895 Tyr Val Asn He Glu Fhe Gly Ser Asp Gin Ser Gly Tyr Leu Ser Gly 900 905 910 Pro Val Ala Fhe His Ser Ser Ero Ser Val Arg Cys .Pro Ser Gin Leu 915 920 925 Gin Ero Ala Pro Arg Glu Glu Glu Thr Gly Thr Glu Glu Tyr Met Lys 930 935 940 Met Asp Leu Gly Ero Gly Arg Arg Ala Ala Trp Gin Glu Ser Thr Gly 945 950 955 960 Val Glu Met Gly Arg Leu Gly Pro Ala Pro Pro Arg Ala Ala Ser He 965 970 975 Cys Arg Iro Thr Arg Ala Val Pro Ser Ser Arg Gly Asp Tyr Met Thr 980 985 990 Met Gin Met Ser Cys Pro Arg Gin Ser Tyr Val Asp Thr Ser Ffco Ala 995 1000 1005 Ala Pro Val Ser Tyr Ala Asp Met Arg Thr Gly He Ala Ala Glu Glu 1010 1015 1020 Val Ser Leu Iro Arg Ala Thr Met Ala Ala Ala Ser Ser Ser Ser Ala 1025 1030 1035 1040 Ala Ser Ala Ser Pro Thr Gly Ero Gin Gly Ala Ala Glu Lsu Ala Ala 1045 1050 1055 His Ser Ser Leu Leu Gly Gly Pxx Gin Gly Pro Gly Gly Met Ser Ala 1060 1065 1070 Fhe Thr Arg Val Asn Leu Ser Ero Asn Arg Asn Gin Ser Ala Lys Val 1075 1080 1085 He Arg Ala Asp Iro Gin Gly Cys Arg Arg Arg His Ser Ser Glu Thr 1090 1095 1100 Fhe Ser Ser Thr Pro Ser Ala Thr Arg Val Gly Asn Thr Val Pro Phe 1105 1110 1115 1120 Gly Ala Gly Ala Ala Val Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser 1125 1130 1135 Glu Asp Val Lys Arg His Ser Ser Ala Ser Fhe Glu Asn Val Trp Leu 1140 1145 1150 Arg Pro Gly Glu Leu Gly Gly Ala Pro Lys Glu Pro Ala Lys Leu Cys 1155 1160 1165 Gly Ala Ala Gly Gly Leu Glu Asn Gly Leu Asn Tyr He Asp Leu Asp 1170 1175 1180 Leu Val Lys Asp Phe Lys Gin Cys .Pro Gin Glu Cys Thr Pro Glu Pro 1185 1190 1195 1200 Gin Pro .Pro Pro Pro Pro Pro .Pro His Gin Iro Leu Gly Ser Gly Glu 1205 1210 1215 Ser Ser Ser Thr Arg Arg Ser Ser Glu Asp Leu Ser Ala Tyr Ala Ser 1220 1225 1230 He Ser Fhe Gin Lys Gin Iro Glu Asp Arg Gin 1235 1240

Claims: CLAIMS 1. A DNA construct comprising a DNA sequence encoding insulin receptor substrate 1 (IRS-1) , the DNA sequence containing a mutation of at least one nucleotide, or comprising a fragment of the DNA sequence including said mutation. 2. A DNA construct according to claim 1, wherein the mutation gives rise to at least one amino acid substitution in the IRS-1 sequence. 3. A DNA construct accroding to claim 2, wherein the mutation is located at a site where the amino acid substitution interferes with signal transduction through IRS-1. 4. A DNA construct according to claim 1, wherein the mutation is a mutation of G to A in the first position of codon 972, a mutation of A to G in the third position of codon 805, a mutation of G to C in the third position of codon 894. 5. A DNA construct according to claim 4, comprising the DNA sequence shown in the Sequence Listing as SEQ ID N0:1, or comprising a fragment of the DNA sequence including a mutation of G to A at nucleotide 3494 of SEQ ID N0:1. 6. A recombinant expression vector comprising a DNA construct according to any of claims 1-5. 7. A living system containing a DNA construct according to any of claims 1-5 or a recombinant expression vector according to claim 6 and capable of expressing IRS-1 wherein at least one amino acid is substituted. 8. A living system according to claim 7 which comprises a •mammalian cell line or a transgenic animal, in particular a transgenic non-human mammal. RECTIFIED SHEET (RULE 91) ISA/SE 9. A method of detecting the presence of a mutation in the gene encoding IRS-1, the method comprising obtaining a biological sample from a subject and analysing the sample for a mutation of at least one nucleotide in the IRS-1 sequence. 10. A method according to claim 9, wherein the sample is analysed for a mutation in the gene encoding IRS-1, which mutation gives rise to at least one amino acid substitution. 11. A method according to claim 9 or 10, wherein the sample is analysed for a mutation located at a site where the amino acid substitution interferes with signal transduction through IRS-1. 12. A method according to claim 11, wherein the sample is analysed for a mutation of G to A in the first position of codon 972 of the gene encoding IRS-1, a mutation of A to G in the third position of codon 805, a mutation of G to C in the third position of codon 894. 13. A method according to claim 9, wherein a biological sample is obtained from a subject, DNA is isolated from the sample and digested with a restriction endonuclease which cleaves DNA at the site of the mutation, and cleavage of the DNA within the gene encoding IRS-1 at this site is determined. 14. A method according to claim 13, wherein the restriction pattern of the DNA after digestion with the restriction endonuclease is compared to the restriction pattern obtained with a negative control comprising at least a portion of wild- type DNA encoding IRS-1. 15. A method according to claim 13, wherein the restriction pattern of the DNA after digestion with the restriction endonuclease is compared to the restriction pattern obtained with a positive control comprising at least a portion of DNA encoding IRS-1 and containing the mutation. RECTIFIED SHEET (RULE 91) ISA/SE 16. A method according to claim 15, wherein the positive control comprises a DNA construct according to any of claims 1- 5. 17. A method according to claim 13, wherein the restriction 5 endonuclease is one which cleaves DNA at the sequence 5'-C C A/T G G-3' 3'-G G T/A C C-3 » 18. A method according to claim 17, wherein the restriction endonuclease is BstNl. 10 19. A method according to claim 13, which further comprises amplifying the DNA isolated from the sample prior to digestion with the restriction endonuclease. 20. A method according to any of claims 9-19 for determining predisposition to NIDDM in a subject. 15 21. A method according to claim 9, wherein a biological sample is obtained from a subject, DNA is isolated from the sample, the DNA is amplified and hybridised to a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a 20 mutation of at least one nucleotide, which mutation corresponds to the mutation the presence of which in the gene encoding IRS- 1 is to be detected, and hybridisation of the probe to the DNA is determined. 22. A method according to claim 21, wherein the amplified DNA 25 is further hybridised to a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the wild-type gene encoding IRS-1, and hybridisation of the probe to the DNA is determined. RECTIFIEDSHEET(RULE91) ISA/SE 23. A method according to claim 21 or 22, wherein the label substance with which the oligonucleotide probe containing the mutation is labelled is different from the label substance with which the oligonucleotide probe corresponding to the wild-type DNA is labelled. 24. A method according to claim 21 or 22, wherein the label is selected from the group consisting of enzymes, coloured or fluorescent substances, and radioactive isotopes. 25. A method according to any of claims 21-24 for determining predisposition to NIDDM in a subject. 26. A diagnostic composition for detecting the presence of a mutation in the gene encoding IRS-1, the composition comprising a DNA construct according to any of claims 1-5. 27. A test kit for detecting the presence of a mutation in the gene encoding IRS-1, the kit comprising (a) a restriction endonuclease which cleaves DNA at the site of the mutation, (b) a first DNA sequence corresponding to at least part of the wild-type gene encoding IRS-1, and/or (c) a second DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a mutation of at least one nucleotide, which mutation corresponds to the mutation the presence of which in the gene encoding IRS-1 is to be detected. 28. A test kit according to claim 27, wherein the second DNA sequence is a DNA construct according to any of claims 2-5. 29. A test kit according to claim 27, wherein the restriction endonuclease is one which cleaves DNA at the sequence RECTIFIED SHEET (RULE 91) ISA/SE 5 * -C C A/T G G-3 ' 3 ' -G G T/A C C-3 ' 30. A test kit according to claim 29, wherein the restriction endonuclease is BstNl. 531. A test kit according to claim 27, which further comprises means for amplifying DNA. 32. A test kit according to any of claims 27-30 for determining predisposition to NIDDM in a subject. 33. A test kit for detecting the presence of a mutation in the 10 gene encoding IRS-1, the kit comprising (a) means for amplifying DNA, and (b) a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the gene encoding IRS-1 and containing a mutation of at least one nucleotide, which 15 mutation corresponds to the mutation the presence of which in the gene encoding IRS-1 is to be detected. 34. A test kit according to claim 33, wherein the labelled oligonucleotide probe comprises a DNA construct according to any of claim 2-5. 2035. A test kit according to claim 33, which further comprises a labelled oligonucleotide probe comprising a DNA sequence corresponding to at least part of the wild-type gene encoding IRS-1. 36. A test kit according to any of claims 33-35, wherein the 25 label is selected from the group consisting of enzymes, coloured or fluorescent substances, and radioactive isotopes. RECTIFIEDSHEET(RULE91) ISA/SE 37. A variant of IRS-1 containing at least one amino acid substitution. 38. A variant according to claim 37 containing at least one amino acid substitution at a site where the substitution 5 interferes with signal transduction through IRS-1, or a fragment thereof including said substitution. 39. A variant according to claim 38, in which glycine 972 is substituted by arginine, or a fragment thereof containing said substitution. 1040. A variant according to claim 39, which has the amino acid sequence shown in the Sequence Listing as SEQ ID NO:2, or a fragment thereof containing Arg 972 . RECTIFIEDSHEET(RULE91) ISA/SE

Inventors: BJOERBAEK CHRISTIAN, FREDERIKSEN KATHRINE ALMIND, PEDERSEN OLUF, BJOERBAEK, CHRISTIAN, FREDERIKSEN, KATHRINE, ALMIND, PEDERSEN, OLUF
Applicants: BJOERBAEK CHRISTIAN, FREDERIKSEN KATHRINE ALMIND, NOVONORDISK AS, PEDERSEN OLUF, BJOERBAEK, CHRISTIAN, FREDERIKSEN, KATHRINE, ALMIND, NOVO NORDISK A/S, PEDERSEN, OLUF
Application year: 1994
Main classification: C07K15
IPC codes: C07K14, C12N15, C12Q1